scholarly journals Biomarker Discovery of Pancreatic and Gastrointestinal Cancer by 2DICAL: 2-Dimensional Image-Converted Analysis of Liquid Chromatography and Mass Spectrometry

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Masaya Ono ◽  
Masahiro Kamita ◽  
Yusuke Murakoshi ◽  
Junichi Matsubara ◽  
Kazufumi Honda ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Liquid Chromatography ◽  
Biomarker Discovery ◽  
Accurate Diagnosis ◽  
Blood Biomarkers ◽  
Proteomics Analysis ◽  
Dimensional Image ◽  
Analysis System ◽  
New Biomarkers ◽  
Colorectal Cancer Patients

Biomarkers tested by blood sample are of great use to clinicians as they provide useful information to aid an early and accurate diagnosis. Comprehensive “omics” studies are expected to facilitate the identification of such new biomarkers, and much research is being performed in this area. Our proteomics analysis system of 2-dimensional image-converted analysis of liquid chromatography and mass spectrometry (2DICAL) has successfully identified several new blood biomarkers from the clinical blood samples of pancreatic and colorectal cancer patients.

Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations

2007 ◽  
Vol 45 (11) ◽  
Author(s):  
Michael Kiehntopf ◽  
Robert Siegmund ◽  
Thomas Deufel
Keyword(s):  
Mass Spectrometry ◽  
Biomarker Discovery ◽  
Clinical Results ◽  
Protein Profiling ◽  
High Throughput Analysis ◽  
Pilot Studies ◽  
Flight Mass Spectrometry ◽  
Analytical Phase ◽  
New Biomarkers ◽  
Tof Ms

AbstractSurface-enhanced laser desorption time of flight mass spectrometry (SELDI-TOF-MS) is an important proteomic technology that is immediately available for the high throughput analysis of complex protein samples. Over the last few years, several studies have demonstrated that comparative protein profiling using SELDI-TOF-MS breaks new ground in diagnostic protein analysis particularly with regard to the identification of novel biomarkers. Importantly, researchers have acquired a better understanding also of the limitations of this technology and various pitfalls in biomarker discovery. Bearing these in mind, great emphasis must be placed on the development of rigorous standards and quality control procedures for the pre-analytical as well as the analytical phase and subsequent bioinformatics applied to analysis of the data. To avoid the risk of false-significant results studies must be designed carefully and control groups accurately selected. In addition, appropriate tools, already established for analysis of highly complex microarray data, need to be applied to protein profiling data. To validate the significance of any candidate biomarker derived from pilot studies in appropriately designed prospective multi-center studies is mandatory; reproducibility of the clinical results must be shown over time and in different diagnostic settings. SELDI-TOF-MS-based studies that are in compliance with these requirements are now required; only a few have been published so far. In the meantime, further evaluation and optimization of both technique and marker validation strategies are called for before MS-based proteomic algorithms can be translated into routine laboratory testing.Clin Chem Lab Med 2007;45:1435–49.

Sign in / Sign up

Export Citation Format

Share Document